Literature DB >> 7848545

Risks and benefits of drugs used in the management and prevention of gout.

P G Conaghan1, R O Day.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are now commonly used for the treatment of acute gout, but caution is required in view of their adverse effects, especially in the elderly. Colchicine is still an effective acute agent, but care must be taken to monitor toxicity. Intra-articular glucocorticosteroid therapy is useful and very safe; oral steroids and corticotrophin (adrenocorticotrophic hormone) may have a small role in acute therapy and seem safe when used over short time spans. Low dose colchicine may have a cost and toxicity advantage over NSAIDs in the prophylaxis of gout when commencing therapy aimed at reducing elevated plasma urate concentrations. Allopurinol is more frequently used than uricosuric agents such as probenecid, and toxicity may be largely avoided by tailoring dosage schedules according to renal function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848545     DOI: 10.2165/00002018-199411040-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  37 in total

1.  What stops a gouty attack?

Authors:  R A Terkeltaub
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 2.  Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs.

Authors:  S B Abramson
Journal:  Curr Opin Rheumatol       Date:  1992-06       Impact factor: 5.006

3.  Gout and hyperuricaemia.

Authors:  R I Faragher; D J Caelli
Journal:  Aust Fam Physician       Date:  1987-06

Review 4.  Nonsteroidal anti-inflammatory drugs. Differential use in older patients.

Authors:  L Girgis; P Brooks
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

5.  Allopurinol hepatotoxicity. Case report and literature review.

Authors:  S K Chawla; H D Patel; G R Parrino; J Soterakis; P A Lopresti; W A D'Angelo
Journal:  Arthritis Rheum       Date:  1977 Nov-Dec

6.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

7.  Desensitization to allopurinol in patients with gout and cutaneous reactions.

Authors:  A G Fam; J Lewtas; J Stein; T W Paton
Journal:  Am J Med       Date:  1992-09       Impact factor: 4.965

Review 8.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

10.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

View more
  5 in total

1.  Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials.

Authors:  Stephen P Juraschek; Edgar R Miller; Allan C Gelber
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

2.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors:  K Turnheim; P Krivanek; R Oberbauer
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

Authors:  Angelo L Gaffo; Kenneth G Saag
Journal:  Core Evid       Date:  2010-06-15

Review 4.  Systemic corticosteroids for acute gout.

Authors:  H J E M Janssens; P L B J Lucassen; F A Van de Laar; M Janssen; E H Van de Lisdonk
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 5.  Gout in the elderly. Clinical presentation and treatment.

Authors:  A G Fam
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 4.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.